Clinical logistics and life science manufacturing leaders Boston Labs and Germfree Laboratories have announced their partnership to launch a new network of mobile CGT manufacturing facilities.
The two companies are combining deep logistics, CGT manufacturing expertise and mobile cleanroom technology to deliver decentralised CGT point-of-care contract manufacturing services.
The CGT mobile manufacturing platform will launch in Boston, MA in the fourth quarter of 2021 and will scale to a network of global point-of-care mobile contract manufacturing centres.
The platforms help overcome the limitations of traditional centralised cost prohibitive CGT manufacturing methods
Boston Labs is embedded within the Boston/Cambridge life science community which is home to more than 1000 biotech companies. 18 of the top 20 biopharmas have a major presence in the area, including Biogen, Novartis, Sanofi and Takeda and other leading companies such as Moderna, Crispr Therapeutics, bluebird bio and Avrobio.
Jon Mason, CEO of Boston Labs said: "As the cell and gene therapy industry continues to grow, easier on-site access to cleanroom manufacturing facilities will likely be highly valued."
Mason added: "Our pivotal partnership with Germfree Laboratories, enables Boston Labs to readily deploy mobile manufacturing platforms to any clinical site globally where CGT trials are enrolling, eliminating logistical risks associated with transporting patient material under a critical timeline. This is the Future of Point-of-Care Cell and Gene Therapy Delivery."
Kevin Kyle, CEO of Germfree said: "This groundbreaking collaboration with Boston Labs should deliver much-needed process space and opportunities to showcase how next-generation cleanrooms and manufacturing facilities can accelerate the processes needed for the future."
This partnership, designed to reduce client CGT manufacturing costs and complexities, delivers secure access to mobile GMP-compliant manufacturing facilities wherever they are needed.
